Business Development in Emerging Markets for the Pharmaceutical Industry, Along with the Regulatory Landscape

Emerging markets (EMs) are increasingly central to pharmaceutical business development due to growing demand, evolving regulatory frameworks, and escalating expectations for quality, safety, and innovation. Between 2023-2025, shifts such as India’s revised Schedule M GMP rules, China’s expanded volume-based procurement, Brazil’s reliance pathways, and heightened traceability requirements in the GCC have reshaped how pharma companies enter, scale, and compete in EMs. This paper analyzes why EMs matter now, which business development models are working best, the changing regulatory landscape, case studies from key markets, and presents a risk/entry evaluation matrix to help companies prioritize. The aim is to guide strategy in a less formal but evidence-grounded style.